Company profile for PassPort Technologies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Based in San Diego, California, on the new GENESIS Science Center campus, PassPort Technologies, Inc. is dedicated to advancing therapeutics through advanced drug delivery systems. Established in July 2019 after being spun out of Nitto Denko Corporation, the company has focused its efforts on research and development, aiming to commercialize the PassPort® transdermal platform. With a commitment to utilizing its patent-protect...
Based in San Diego, California, on the new GENESIS Science Center campus, PassPort Technologies, Inc. is dedicated to advancing therapeutics through advanced drug delivery systems. Established in July 2019 after being spun out of Nitto Denko Corporation, the company has focused its efforts on research and development, aiming to commercialize the PassPort® transdermal platform. With a commitment to utilizing its patent-protected drug delivery platform, PassPort Technologies seeks to create enhanced pharmaceutical products through innovative and efficient delivery methods.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Suite 120, San Diego, CA 92121
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/passport-technologies-inc-announces-positive-interim-phase-i-results-of-zolmitriptan-transdermal-microporation-system-for-the-treatment-of-acute-migraine-302103063.html

PR NEWSWIRE
29 Mar 2024

https://www.prnewswire.com/news-releases/passport-technologies-inc-initiated-us-phase-i-clinical-trial-of-zolmitriptan-transdermal-microporation-system-for-the-treatment-of-acute-migraine-302070038.html

PR NEWSWIRE
23 Feb 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty